13F filing recap · Q4 2024
What did Hillman Capital Management buy in Q4 2024?
Reported stock-position changes between this filing and the previous one. US-listed stocks across every Hillman account, including accounts that belong to no fund below.
Stock value
$269.56M
Positions
54
Estimated turnover
29.5%
Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.
Quarter in review
Hillman Capital Management opened new positions in ASML Holding, Diageo, Brown-Forman, and several smaller names including an Invesco S&P 500 Equal Weight ETF, while exiting Emerson Electric, Nordstrom, ServiceNow, Simon Property Group, Wells Fargo, and Medtronic. The firm substantially added to Nike and Pfizer, and dramatically increased its SPDR S&P 500 ETF Trust stake. Boeing, Estée Lauder, GSK, and Biogen saw moderate increases, while Bristol-Myers Squibb, US Bancorp, Intel, and Warner Bros. Discovery were moderately trimmed.